Cinética del lactato para el pronóstico en el shock cardiogénico asistido con oxigenador extracorpóreo de membrana venoarterial / Lactate levels as a prognostic predict in cardiogenic shock under venoarterial extracorporeal membrane oxygenation support

Introducción y objetivos: El lactato y su evolución se asocian con el pronóstico de los pacientes en shock, si bien es escasa la evidencia en aquellos asistidos con oxigenador extracorpóreo de membrana venoarterial (ECMO-VA). Nuestro objetivo es evaluar su valor pronóstico en shock cardiogénico asistido con ECMO-VA. Métodos: Estudio de pacientes tratados con ECMO-VA por shock cardiogénico de indicación médica entre julio de 2013 y abril de 2021. Se calculó el aclaramiento de lactato: (lactato inicial − lactato 6 h) / lactato inicial × tiempo exacto entre ambas determinaciones. Resultados: De 121 pacientes, 44 (36,4%) tenían infarto agudo de miocardio; 42 (34,7%), implante intraparada; 14 (11,6%), tromboembolia pulmonar, 14 (11,6%), tormenta arrítmica y 6 (5,0%), miocarditis fulminante. A los 30 días habían fallecido 60 pacientes (49,6%); la mortalidad fue mayor con el implante intraparada que con el implante en circulación espontánea (30 [71,4%] de 42 frente a 30 [38,0%] de 79; p=0,030). Se asociaron de manera independiente con la mortalidad a 30 días la alanina aminotransferasa (ALT) antes del implante y el lactato (tanto basal como a las 6 h y el aclaramiento). Los modelos de regresión que incluían el lactato presentaron mejor capacidad predictiva de la supervivencia que las puntuaciones ENCOURAGE y ECMO-ACCEPTS, con mayor área bajo la curva ROC en el modelo con lactato a las 6 h.Conclusiones: El lactato (basal y a las 6 h y el aclaramiento) es un predictor independiente para el pronóstico de los pacientes en shock cardiogénico asistidos con ECMO-VA que facilita una mejor estratificación del riesgo y tiene una capacidad predictiva superior (AU)

Introduction and objectives: Lactate and its evolution are associated with the prognosis of patients in shock, although there is little evidence in those assisted with an extracorporeal venoarterial oxygenation membrane (VA-ECMO). Our objective was to evaluate its prognostic value in cardiogenic shock assisted with VA-ECMO. Methods: Study of patients with cardiogenic shock treated with VA-ECMO for medical indication between July 2013 and April 2021. Lactate clearance was calculated: [(initial lactate − 6 h lactate) / initial lactate × exact time between both determinations]. Results: From 121 patients, 44 had acute myocardial infarction (36.4%), 42 implant during cardiopulmonary resuscitation (34.7%), 14 pulmonary embolism (11.6%), 14 arrhythmic storm (11.6%), and 6 fulminant myocarditis (5.0%). After 30 days, 60 patients (49.6%) died, mortality was higher for implant during cardiopulmonary resuscitation than for implant in spontaneous circulation (30 of 42 [71.4%] vs 30 of 79 [38.0%], P=.030). Preimplantation GPT and lactate (both baseline, at 6hours, and clearance) were independently associated with 30-day mortality. The regression models that included lactate clearance had a better predictive capacity for survival than the ENCOURAGE and ECMO-ACCEPTS scores, with the area under the ROC curve being greater in the model with lactate at 6 h. Conclusions: Lactate (at baseline, 6h, and clearance) is an independent predictor of prognosis in patients in cardiogenic shock supported by VA-ECMO, allowing better risk stratification and predictive capacity (AU)

Bacteriemia por Capnocytophaga y embolismos pulmonares / Capnocytophaga bacteriemia and pulmonary embolism

No disponible

Anemia secundaria a infección por parvovirus B19 en adulto joven, previamente asintomático / Anemia associated with parvovirus B19 infection in a young adult without underlying disease

No disponible

[Primary angioplasty is elective reperfusion therapy in the treatment of acute myocardial infarction. Arguments in favor]. / La angioplastia primaria es la terapéutica de reperfusión de elección en el tratamiento del infarto agudo de miocardio. Argumentos a favor.

Thrombolytic treatment has demonstrated its efficacy on acute myocardial infarction. However, it cannot be used in a significant number of patients and it doesn't achieve adequate reperfusion in a great percentage of cases. Primary angioplasty, a treatment which can be used in the majority of acute myocardial infarction patients, obtains artery patency in more than 90% of cases, with a better perfusion in the infarct territory and fewer reocclusion rates compared to thrombolysis. Consequently, primary angioplasty is associated with a lower mortality rate, and a lower incidence of recurrent ischemia and hemorrhagic stroke during hospitalization. Coronary artery stents and new antiplatelet agents have improved the short-term and mid-term results of primary angioplasty. Currently, when the facilities and trained personal are available, primary angioplasty should be the treatment of choice in acute myocardial infarction.

[Reversible severe ventricular dysfunction in female patient with eclampsia and HELLP syndrome]. / Disfunción ventricular severa reversible en una paciente con eclampsia y síndrome HELLP.

A 23 year-old primigravid woman presented eclampsia and HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) with severe left ventricular dysfunction after having a cesarean section. In a few weeks, clinic disappeared and ventricular function normalized. The importance of differential diagnosis between ventricular dysfunction in eclampsia and peripartum myocardiopathy is discussed.

[The intracoronary infusion of superoxide dismutase during the initial liberation of oxygen free radicals induced by reperfusion. The effect on the infarct size after 60 minutes of coronary occlusion in the pig model]. / Infusión intracoronaria de superóxido dismutasa durante la liberación inicial de radicales libres del oxígeno inducida por la reperfusión. Efecto sobre el tamaño del infarto tras 60 minutos de oclusión coronaria en el modelo porcino.

The role of oxygen free radicals (OFR) generated early during myocardial reperfusion in the genesis of myocardial necrosis was studied in 26 pigs submitted to transient coronary occlusion followed by one of three different reperfusion protocols. In group A, a selective intracoronary infusion of a Ringer solution was started after 60 min of coronary occlusion, and reperfusion was performed 4 min later. The infusion was maintained during the first 6 min of reperfusion at a rate of 3 ml/min. In group B, the Ringer solution administered during reperfusion contained a high concentration (2.778 U/ml) of superoxide dismutase (SOD). In group C, reperfusion was performed after 60 min of coronary occlusion with no intracoronary infusion. Twenty-four hours later the heart was excised and the area at risk and infarct size were measured by in vivo fluorescein injection and triphenyl-tetrazolium chloride staining respectively. The area at risk was similar in the 3 groups: 15.03 +/- 2.6%, 13.26 +/- 3.3% and 16.34 +/- 6.7% of ventricular mass in groups A, B, and C, respectively (p = 0.42). No differences between groups were observed in infarct size, either when measured as a percent of ventricular mass (10.04 +/- 3.8%, 9.31 +/- 3.8% and 10.1 +/- 2.4% in groups A, B, and C, p = 0.91) or as a percent of the area at risk (64.63 +/- 18.5%, 67.81 +/- 16.1%, and 61.35 +/- 6.7%, respectively, p = 0.72). Thus, the intracoronary administration of SOD during the early reperfusion has not beneficial effect on infarct size. This results suggest that the early burst of OFR is not a major determinant of infarct size in the pig.